Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
Esophageal cancer is an exceedingly aggressive and malignant cancer that imposes a substantial burden on patients and their families. It is usually treated with surgery, chemotherapy, radiotherapy, and molecular-targeted therapy. Immunotherapy is a novel treatment modality for esophageal cancer wher...
Guardado en:
Autores principales: | Yu-Ge Zhu, Bu-Fan Xiao, Jing-Tao Zhang, Xin-Run Cui, Zhe-Ming Lu, Nan Wu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8b6f5dbffe974ed58a174342600c2fad |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
How Can We Engineer CAR T Cells to Overcome Resistance?
por: Glover M, et al.
Publicado: (2021) -
Spinoculation and retronectin highly enhance the gene transduction efficiency of Mucin-1-specific chimeric antigen receptor (CAR) in human primary T cells
por: Alireza Rajabzadeh, et al.
Publicado: (2021) -
Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
por: Camilla M. Grunewald, et al.
Publicado: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Cristina Aparicio, et al.
Publicado: (2021) -
The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy
por: Hamilton G, et al.
Publicado: (2021)